Shenzhen Vienomics Bio Tech Overview
- Founded
- 2016
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $7.23M
- Investors
- 3
Shenzhen Vienomics Bio Tech General Information
Description
Developer of screening technologies intended to reduce the incidence of cancer. The company's technologies are based on ultra-deep gene sequencing technology, bioinformatics analysis and big data analysis which helps in detecting cancer in precancerous lesions or at the early-stage, providing patients with increased chances of survival and reduced mortality rates.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 5th Floor, Building B, Xili Shiwai Taoyuan Creative Park
- Nanshan District
- Shenzhen
- China
+86 0755 0000 0000
Shenzhen Vienomics Bio Tech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 01-Nov-2018 | $7.23M | 000.00 | Completed | Startup | |
| 2. Early Stage VC | 01-Jan-2017 | 00.000 | 00.000 | Completed | Startup | |
| 1. Angel (individual) | 01-Jan-2016 | $1.55M | $1.55M | Completed | Startup |
Shenzhen Vienomics Bio Tech Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Chaoyu Liu Ph.D | Chief Executive Officer | ||
| Peng Chen | Chief Financial Officer | ||
| Chuanbo Xu Ph.D | Chief Medical Officer |
Shenzhen Vienomics Bio Tech Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| AMER International Group | Corporation | Minority | 000 0000 | 000000 0 | |
| Qianjiang Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| ASBV China | Venture Capital | Minority | 000 0000 | 000000 0 |